GRAL NASDAQ
GRAIL, Inc.
1W: +9.8%
1M: +29.0%
3M: +35.1%
YTD: -23.6%
1Y: +72.6%
$67.19
-0.67 (-0.99%)
Weekly Expected Move ±11.3%
$46
$53
$60
$66
$73
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (73)
This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street
Here's Why Grail Shares Popped Higher This Week
Grail (GRAL) Q1 2026 Earnings Transcript
GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations
GRAIL Reports First Quarter 2026 Financial Results
Earnings Scheduled For May 5, 2026
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
GRAIL, Inc. $GRAL Shares Sold by Carnegie Investment Counsel
Aaron Freidin Sells 45,806 Shares of GRAIL (NASDAQ:GRAL) Stock
Joshua Ofman Sells 61,665 Shares of GRAIL (NASDAQ:GRAL) Stock
Robert Ragusa Sells 123,502 Shares of GRAIL (NASDAQ:GRAL) Stock
GRAIL rated new Neural at Mizuho and Piper after study setback
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Rating of “Moderate Buy” from Brokerages
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
Grail, Epic Plan Galleri Test Integration For 450 Health Systems
Aberdeen Group plc Sells 144,512 Shares of GRAIL, Inc. $GRAL
Better Healthcare Stock to Own in a Recession: Defensive or Growth?
Grail partnering with Superpower to offer Galleri cancer early detection test
Here's Why Grail Stock Soared Higher This Week
This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month
Here's Why Grail Shares Crushed the Market This Week
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
GRAIL (NASDAQ:GRAL) Shares Up 6.9% Following Analyst Upgrade
Grail upgraded at TD Cowen; says selloff is buying opportunity
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Recommendation of “Hold” from Analysts
GRAIL announces leadership transition
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity
Citigroup Inc. Sells 14,963 Shares of GRAIL, Inc. $GRAL
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Here's Why Grail Stock Bounced Back 16% Today
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
Lost Money on GRAIL, Inc. (GRAL)? Possible Fraud - Contact Levi & Korsinsky Today
Here's Why Grail Stock Bounced Back 16% Today
GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm
Why Grail Shares Are Plummeting
Here's Why Grail Stock Slumped Again Today
Here's Why Grail Stock Slumped Again Today
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
GRAIL Stock Tumbles — National Health Service Galleri Trial To Blame
'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection
Trending stocks as Wall Street ends higher despite cooling growth, Supreme Court tariff ruling
Hims latest offering, Grail's Galleri cancer test, fails U.K. study
Grail Shares Crashes 50% After Major Cancer Screening Trial Fails Main Goal
This once-hot cancer-detection company's stock got cut in half after a failed trial
GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Here's Why Grail Stock Crashed 50% Today
GRAIL GAAP EPS of -$2.44 beats by $0.22, revenue of $43.6M beats by $122.0K
Biotech Stock Plummets on Cancer Screening Trial Results
Biggest stock movers Friday: OPEN, AKAM, and more
Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction
Grail shares plunge after major cancer screening trial misses main goal
Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.
GRAIL reiterates 22%-32% Galleri sales growth guidance for 2026 while expanding sales force after NHS-Galleri trial
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
GRAIL (GRAL) Projected to Post Earnings on Thursday
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
A Study on Aging Unlocks Holy Grail of Sports Performance
Here's Why This Exciting Healthcare Stock Popped 13% Today
GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GRAIL, Inc. $GRAL Shares Sold by Cwm LLC
Carnegie Investment Counsel Increases Stake in GRAIL, Inc. $GRAL
Trump Media CEO: 'NUCLEAR FUSION is the HOLY GRAIL'
GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference
64,560 Shares in GRAIL, Inc. $GRAL Bought by Caxton Associates LLP
Here's Why Grail Soared, Again, in November
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
An Auto Holy Grail: Motors That Don't Rely on Chinese Rare Earths
Why GRAIL Stock Could Be Biotech's Next Big Breakout